Trygg PharmaAS, a company jointly owned by Aker BioMarine ASA, a Norwegian biotechnology company, and Lindsay Goldberg, a New York-based investment fund, has acquired 100 percent of the shares in EPAXAS from Austevoll Seafood ASA. EPAXAS is a world-leading supplier of concentrated, marine-derived omega-3 formulas that target specific health conditions.
"EPAX is fortunate to get an owner that will invest significantly in people, products, processes, and technology in Aalesund," said Bjørn Refsum, managing director of EPAX. "This ownership change will be a great benefit to our customers and ensure further progress in the omega-3 field."
Refsum noted that throughout EPAX's 170-year corporate history, ownership changes have naturally occurred and that the company's experiences from these processes have always been positive.
"Trygg Pharma's ownership will open up new opportunities and markets. Combining resources with such a highly regarded company that places major emphasis on research and development will benefit our customers, employees and partners and is making EPAX even stronger," said Refsum.
As part of the agreement between Trygg Pharma AS and Austevoll Seafood, EPAX has entered into a long-term supply agreement with Austral S.A., a subsidiary of Austevoll Seafood. The agreement will ensure continued cooperation between EPAX and Austral, and secure supply of the highest quality crude fish oil from sustainable and traceable sources.
Under its new ownership, EPAX will immediately invest significantly in expanding the capacity of the factory in Aalesund, Norway. "The planned capacity expansion means that our customers can rest assured that EPAX will be able to grow with them in the future," said Refsum.
About Aker BioMarine ASA and Lindsay Goldberg: Aker BioMarine ASA is a Norwegian publicly traded, fully integrated biotechnology company that combines expertise in deepwater fishing and harvesting with marine biotechnology. Aker BioMarine utilizes its unique krill harvesting to develop its own downstream operations within the high value added nutraceutical and aquaculture feed markets. Aker BioMarine has registered Superba as the company’s brand name for nutraceutical and Qrill as the company's brand name for its krill meal and krill oil products for aquaculture. Aker ASA owns 83 percent of Aker BioMarine ASA shares.
Lindsay Goldberg is a New York-based partnership that manages $10 billion of equity capital and is focused on acquiring well-managed businesses and actively helping to build long-term value. Lindsay Goldberg is a trusted and experienced partner with a successful track record of investing across a wide range of industries and helping companies fully meet their long-term potential.
About EPAX AS: EPAX AS offers concentrated marine omega-3 oils in the business-to-business segment under the brand name EPAX®, available in a wide range of top-quality formulas with different EPA/DHA ratios and concentrations focused on specific health conditions, available in TG and EE versions. EPAXAS is headquartered in Aalesund with a global sales office in Lysaker/Oslo, Norway. Its production facility in Aalesund is GMP-approved by the Norwegian Medicines Agency for the manufacturing of API products. The company's operation is certified by Friend of the Sea (FOS) to have a documented sustainable operation—from the fish harvesting in Peru to its finished omega-3 ingredients in Norway. For further information on EPAXAS, its products or clinical studies visit http://www.epax.com or contact marketing manager Gunilla Traberg at [email protected]